EC
BMY.RT

EcoR1 Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

EcoR1 Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,748,300
Closed -$17M – 67
2020
Q2 		$17M Buy
4,748,300
+2,500,000
+111% +$9.02M 1.26% 22
2020
Q1 		$8.54M Buy
+2,248,300
New +$7.41M 0.89% 30

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

EcoR1 Capital's BMY.RT Position: Q3 2020 in Review

EcoR1 Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 4,748,300 shares — an estimated $17M sold.

EcoR1 Capital first reported a position in BMY.RT in Q1 2020 and held it in 2 quarters. The position peaked at $17M in Q2 2020. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • EcoR1 Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
  • EcoR1 Capital sold 4,748,300 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020, an estimated $17M.
  • EcoR1 Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 2 quarters.
  • EcoR1 Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $17M in Q2 2020.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on EcoR1 Capital's 13F filing for Q3 2020, filed 16 Nov 2020.